APMD vs AURA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
APMD · Apnimed$16.09 ▼ 6.70%
AURA · Aura Biosciences$6.87 ▼ 1.58%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- APMD -35.6%
- AURA -2.0%
Head to head
| Metric | APMD | AURA |
|---|---|---|
| Price | $16.09 | $6.87 |
| Change today | ▼ 6.70% | ▼ 1.58% |
| Market cap | $669.84M | $714.99M |
| Return, 3 months | -37.2% | -13.0% |
| Return, year to date | – | +26.1% |
| Return, 1 year | – | +26.3% |
| P/E (TTM) | 4.1 | – |
| P/B | 2.4 | 2.5 |
| P/E percentile vs own 5y | 35th | 46th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -29.4% | – |
| Net profit growth (YoY) | +281.3% | -22.7% |
| Gross margin | 93.9% | – |
| Operating margin | 30.9% | – |
| Net margin | 252.6% | – |
| Return on equity | – | -61.7% |
| Analyst target vs. price | +212.8% | +162.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 43 | 51 |
| 30-day volatility | 80.1% | 64.9% |
| Max drawdown, 1 year | -56.5% | -32.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AURA is the largest of the group by market value.
- AURA has been the calmest stock over the last 30 days.